The peripheral nerves are responsible for carrying signals between the brain, spinal cord, and muscles. These signals control movement, coordination, reflexes, and muscle strength. In dogs affected by LPN1, a genetic mutation disrupts normal nerve function and maintenance, causing gradual degeneration of nerve fibers over time. As nerves deteriorate, communication between the nervous system and muscles becomes increasingly impaired, leading to progressive weakness and loss of motor control.
Clinical signs of LPN1 typically appear in young to middle-aged dogs, although onset and severity can vary. Early symptoms may be subtle and include reduced exercise tolerance, mild hind limb weakness, or reluctance to engage in prolonged activity. As the disease progresses, dogs often develop more obvious neurological signs such as unsteady gait (ataxia), difficulty rising, and decreased stamina.
Muscle wasting (atrophy), especially in the hind limbs, is a common feature as affected nerves fail to properly stimulate muscle activity. Over time, dogs may show a wide-based stance, dragging of the hind limbs, and difficulty maintaining balance during walking or running. Reflexes may become reduced, and coordination progressively worsens. In advanced stages, mobility can be significantly impaired, greatly affecting quality of life.
The LPN1 DNA Health Test is designed to detect the specific genetic mutation responsible for Leonberger Polyneuropathy type 1. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Because DNA remains constant throughout life, testing can be performed at any age, including in puppies before symptoms develop.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the LPN1 mutation and is not expected to develop or pass on the disease.
- Carrier: The dog carries one copy of the mutation but typically does not show clinical signs. However, it can pass the mutation to offspring.
- Affected/At Risk: The dog carries two copies of the mutation and is expected to develop progressive neurological signs associated with LPN1.
Genetic testing for LPN1 is highly valuable for breeders, veterinarians, and dog owners. Breeders can use results to make informed breeding decisions that help reduce the prevalence of polyneuropathy in the breed while maintaining healthy genetic diversity. Avoiding carrier-to-carrier matings is essential to prevent affected puppies.
For dog owners, understanding a dog’s genetic status allows for early monitoring and supportive care. While there is currently no cure for LPN1, supportive management such as physiotherapy, controlled exercise, mobility assistance, and regular neurological evaluations can help maintain comfort and quality of life for affected dogs.
The Leonberger Polyneuropathy (LPN1) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited peripheral nerve disorder in future generations.
